Fiber Fortification in GLP-1 Foods: Research Trends, Innovation Gaps & Opportunities
Around 12% of U.S. adults have used a GLP-1 drug such as semaglutide, tirzepatide, or a similar medication, and about 6% are using one today. These drugs reduce appetite and slow digestion, which means many users now eat much smaller portions than before. That shift is creating a new problem for food and beverage companies. […]
Top 6 Skin Microbiome White Spaces Beauty R&D Teams Should Watch
More than 35% of new skincare launches in 2024 used probiotics, prebiotics, or postbiotics. Barrier repair and hydration made up about 41% of microbiome cosmetic applications. Broader microecological skincare reached about $3.2 billion and is expected to grow at 8.3% CAGR through 2032. Yet most R&D teams still crowd around the same ideas: barrier repair, […]
Skin Microbiome Claims and Regulatory Risk: How Fragmented Global Rules Are Forcing Ingredient Strategy Decisions
Over 40% of 2024 skincare launches featured microbiome-related ingredients. Yet approximately 90% of products labeled as “probiotic” actually contain postbiotics (ferments, lysates, filtrates) with no live bacteria present. That gap is not just a labeling inconvenience. It is an active regulatory exposure that is getting harder to ignore as FDA enforcement under MoCRA (Modernization of […]
Emerging Technologies in Skin Microbiome for Barrier Repair
Cosmetic R&D teams are being asked to build skin microbiome portfolios while one core question remains unresolved: do barrier repair products need live bacteria, or can non-living microbial ingredients deliver the same functional benefits? The market has already made its near-term choice. About 90% of cosmetic products labeled “probiotic” actually contain postbiotics, and postbiotics now […]
Commercial and Patent Landscape of Fiber-Fortified Products Targeting GLP-1 Users
An estimated 15 million U.S. adults currently use GLP-1 receptor agonist medications such as semaglutide and tirzepatide, with that figure projected to reach 30 million by 2030. The global GLP-1 drugs market size began at US$ 52.95 billion in 2025 and is forecast to rise to US$ 58.05 billion by 2026. By the end of […]
Challenges and Opportunities in Precision Fermentation for Alternative Protein: What R&D Teams Should Prioritize Next!
Precision fermentation is moving from early technical promise to commercial scale-up. GFI notes that fermentation-enabled protein production has expanded from a niche area into a global food solution producing bioidentical animal proteins and functional ingredients. In 2025, more than 163 specialized companies were active in the sector, while companies in the fermentation ecosystem raised $632 […]
Emerging Technologies in Precision Fermentation for Alternative Proteins
Precision fermentation for alternative proteins now includes 165 companies and $4.8 billion in cumulative investment. Research activity is growing at about 30% annually, yet the field still faces a clear cost-parity challenge. Production titers above 50 g/L as a critical threshold for economic viability, while downstream processing can account for 50–80% of production expenses. With […]
